Introduction {#S1}
============

Vulvovaginal candidiasis (VVC) is one of the most frequent diseases of the female genital tract at reproductive age, affecting 75% of women at least once in their life time ([@B13]). Approximately 5% of VVC cases develop into a severe form of the disease known as recurrent vulvovaginal candidiasis (RVVC), which is characterized by more than three episodes in a one-year period ([@B15]). *Candida albicans* is the most frequent species in VCC and RVVC cases, although fluconazole-resistant and *Candida* non-*albicans* strains (CNA, eg., *C. glabrata*) are also associated with RVVC ([@B17]; [@B15]).

The treatment of VVC can be performed using topical drug formulations, most frequently vaginal creams containing imidazole, triazole or nystatin, which are administered once a day for up to 14 days ([@B32]). In contrast, RVVC requires longer antifungal therapy using topical formulations administered for up to 6 months ([@B32]); alternatively, oral administration with fluconazole or itraconazole for up to 6 months may be required ([@B32]). As an alternative for RVVC treatment, amphotericin B (AMB) intravaginal suppository or vaginal cream are used due to their strong fungicidal effect and broad antifungal spectrum; in addition, resistance to AMB is rare ([@B18]; [@B9]).

Previous studies demonstrated that miltefosine (MFS) has fungicidal effect and a broad-spectrum of activity, including against fluconazole-resistant *Candida* spp. isolates, demonstrating that it is a potential drug for the treatment and/or prevention of fungal infections ([@B50]; [@B16]; [@B47], [@B45]; [@B41]). MFS is an alkylphosphocholine compound initially investigated as an anticancer agent and currently recommended for the treatment of leishmaniasis ([@B16]; [@B2]). However, MFS has important side effects upon oral or systemic administration. The main side effects of oral MFS are related to its surfactant properties and include gastrointestinal discomfort; systemically, MFS has hemolytic and hepatic effects ([@B16]).

Incorporation into nanocarriers improves the pharmacological characteristics of antifungals such as AMB and MFS ([@B12]; [@B42]; [@B40]), enabling prolonged drug release with reduced toxicity, administration frequency, dose and costs. Alginate-based nanocarriers can be used to encapsulate antifungals (azoles and polyenes) ([@B42]), with the important advantage that alginate is non-toxic, non-immunogenic, biodegradable, biocompatible, and mucoadhesive ([@B8]; [@B33]). Recently, our group showed that alginate nanoparticles can be used as MFS delivery systems, promoting sustained release and leading to a significant reduction of hemolytic effect and toxicity in a *Galleria mellonella* larval model ([@B41]). Using this larval model, we also demonstrated the efficacy of miltefosine-loaded alginate nanoparticles (MFS-AN) for treatment of cryptococcosis and candidiasis ([@B41]).

Microemulsions (ME) are thermodynamically stable lipid nanocarriers composed of droplets in the nanometer range (generally 10--100 nm); they improve drug efficacy and bioavailability, and can be used as carriers of lipophilic and hydrophilic molecules ([@B34]; [@B44]; [@B5]). Moreover, depending on composition, ME can undergo phase transformation forming liquid-crystalline gels *in vivo* upon uptake of vaginal fluids, providing sustained drug release at the site of administration ([@B35]).

The aim of this study was to evaluate the antifungal efficacy of AMB and MFS in alginate- and lipid-based nanocarriers in a murine model of vaginal candidiasis. Here, the efficacy and administration frequency necessary for treatment with different topical formulations were assessed and compared with those of a conventional cream formulation currently used against human vaginal candidiasis.

Materials and Methods {#S2}
=====================

Microorganisms {#S2.SS1}
--------------

The reference strain *C. albicans* (SC5314) was stored in brain heart infusion broth (BHI, Becton, Dickinson and Company, United States) with 20% glycerol at −80°C and recovered in Sabouraud dextrose medium at 35°C, for 24--48 h. Yeasts were maintained on Sabouraud dextrose agar (SDA, Becton, Dickinson and Company, United States) at 4°C and subcultured in the same medium at least twice, at 35°C for 24 h, to obtain optimum fungal growth before assays.

Drugs {#S2.SS2}
-----

Miltefosine (MFS, Cayman Chemical Company, United States) was diluted in sterile distilled water or propylene glycol and amphotericin B deoxycholate (AMB, Sigma-aldrich, United States) was diluted in dimethylsulfoxide (DMSO, Sigma-aldrich, United States). Both drugs were diluted prior to preparation of the formulations, as described below.

Antifungal Susceptibility Testing {#S2.SS3}
---------------------------------

To confirm the minimum inhibitory concentration (MIC) values for AMB and MFS, the antifungal susceptibility testing was performed by the broth microdilution technique using the Clinical and Laboratory Standards Institute protocol M27 ([@B10]).

Vaginal Cream Formulations {#S2.SS4}
--------------------------

The conventional vaginal cream formulations were prepared using 10% Polawax wax, 2% mineral oil, and 5% propylene glycol (in distilled water at pH 4.5) ([@B14]); containing either 1.25% amphotericin B (AMB-CR) or 2% miltefosine (MFS-CR).

Microemulsion Formulations {#S2.SS5}
--------------------------

A non-aqueous microemulsion (ME), in which water was replaced by propyleneglycol, was prepared as previously described ([@B6]), by mixing 20% propyleneglycol, 24.8% phosphatidylcholine, 5.6% tricaprilin, and 49.6% monoolein in a 37°C water bath until completely dissolved. Then, 1.25% AMB (AMB-ME) or 2% MFS (MFS-ME) were incorporated into the microemulsion. To confirm that the ME formulation would swell upon contact with the aqueous environment of the vagina, 100 mg ME were placed in contact with 500 μl of distilled water and incubated in a 37°C water bath for 48 h. The percentage of water absorbed by the formulation was determined as the difference between the weight before and after incubation with distilled water, and the types of liquid crystalline phases formed were assessed by polarized light microscopy, in a Leica DM2700P microscope equipped with a Leica DMC 2900 camera (Leica Microsystems, Germany).

Alginate Nanoparticle Formulation {#S2.SS6}
---------------------------------

A formulation of MFS encapsulated in alginate nanoparticles (MFS-AN) was prepared by emulsification using the external gelation method, as previously described ([@B25]; [@B41]). Briefly, 3 mg MFS were dissolved in 1% (w/v) sodium alginate aqueous solution and mixed with 3% (w/v) sorbitan monooleate (SPAN 80) in sunflower oil to form an emulsion. Induction of nanoparticle formation was triggered by dripping 0.2 M CaCl~2~ with 0.5% polaxamer into the emulsion, under constant stirring. Then, the formulation was centrifuged and resuspended in 10% trehalose before freeze-drying, to obtain a fine powder ([@B25]; [@B41]). The mean size (Dz), polidispersion (Pdi), and zeta potential (ζ) of nanoparticles were measured in a Zetasizer NanoZS90 particle analyzer (Malvern Instruments, Worcestershire, United Kingdom). The lyophilized powder showed physical-chemical stability and *in vitro* antifungal activity for up to 30 days ([@B25]; [@B41]). For the *in vivo* assay MFS-AN (2% MFS) was incorporated in 1% (w/v) alginate gel.

Animals {#S2.SS7}
-------

Female BALB/c mice (6--8 weeks old) were kept in pathogen-free conditions at the Laboratory of Animal Experimentation, Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo (ICB, USP, São Paulo, Brazil). Food and water were provided *ad libitum* and all animals were treated according to the practices recommended by The National Institute of Health Animal Care guidelines ([@B11]). The experimental procedure proposed here (vaginal infection model and antifungal treatment) was reasoned according [@B23] and [@B14] ([Supplementary Figure S1](#DS1){ref-type="supplementary-material"}), and was previously approved by the Ethics Committee on the Use of Animals (CEUA, ICB, USP; protocol no. 6439).

### Vaginal Infection {#S2.SS7.SSS1}

The pseudoestrous phase was induced in female BALB/c mice by subcutaneous administration of 0.5 mg of 17-β-valerate-estradiol dissolved in 1 ml of sesame oil, 3 days before the establishment of vaginal infection ([@B23]). Vaginal infection was established by intravaginal inoculation of 3 × 10^6^ *C. albicans* yeasts suspended in 10 μl of sterile PBS.

### Treatment {#S2.SS7.SSS2}

Animals were divided into eight groups (*n* = 7 animals/group), and subjected, 24 h post-infection to one of the following treatments: MFS or AMB in a vaginal cream applied once a day for 6 days (MFS-CR(6×) and AMB-CR(6×) groups); MFS or AMB in microemulsion, administered every 2 days (three doses; AMB-ME(3×) and MFS-ME(3×) groups) or as a single dose (AMB-ME(1×) and MFS-ME(1×) groups); MFS in alginate nanoparticles, administered as a single dose (MFS-AN(1×) group); and an untreated group ([Supplementary Figure S1](#DS1){ref-type="supplementary-material"}). In addition, ME and AN groups (empty carriers) were included as controls. For each treatment dose, 30 μl of formulation were applied to the vaginal canal (∼0.64 mg of MFS in each formulation). On the 7th day post-infection, the animals were euthanized in a CO~2~ chamber and vaginal tissue was collected for mycological and histopathological analyses.

### Mycological and Histopathological Analyses {#S2.SS7.SSS3}

For mycological analysis, five vaginas were excised, weighed, macerated and homogenized in 1 ml of sterile PBS. Serial dilutions (1:10) of the vaginal tissue homogenates were plated onto Sabouraud dextrose agar containing chloramphenicol (50 μg/ml) and incubated at 35°C for 48 h, and the number of colony forming units per gram of vaginal tissue (CFU/g) was determined by manual counting.

For histopathological analysis, the vaginas of two animals were excised, fixed with 10% formaldehyde in PBS and processed for conventional histological analysis using hematoxylin and eosin staining. Samples were analyzed by light microscopy in a Leica DM750 light microscope (Leica Microsystems, Germany), at 400× magnification. The fungal load was determined semi-quantitatively according to the scale: 0, no fungal load; + 1, up to five fungal elements per section; +2, ≥6 fungal elements per section; + 3, from 6 to 50 fungal elements per field; + 4, more than 50 fungal elements per field ([@B36]).

### *In vivo* Imaging System {#S2.SS7.SSS4}

The fluorescent dye Alexa Fluor^®^ 647 (Catalog no. A20106, Molecular Probes, United States) was used to evaluate the persistence of formulations in the vaginal canal, by whole body *in vivo* bioimaging. The following groups were included in these experiments: vaginal cream with Alexa Fluor 647 (CR + AF), microemulsion with or without Alexa Fluor 647 (ME + AF and ME groups, respectively), and alginate nanoparticles with or without Alexa Fluor 647 (AN + AF and AN groups, respectively) (*n* = 3 animals/group). The production of nanocarriers containing Alexa Fluor was performed as described in the previous sections wherein the fluorescent dye was added after production of formulation (vaginal cream and microemulsion) or it was dissolved in 1% (w/v) sodium alginate aqueous solution for incorporation in the alginate nanoparticles. Alexa fluor 647 is not expected to chemically interact/react with the nanocarriers, but to dissolve in the aqueous phase ([@B7]). The fluorescent dye was chosen for this assay because is a hydrophilic compound, that can be dissolved and incorporated in the nanocarriers, and its fluorescent signal do not interfere the auto-fluorescence from hair follicles and other skin structures of mice ([@B30]).

Mice were anesthetized with isoflurane (Cristália, São Paulo, Brazil) and 30 μl of each formulation were administered intravaginally. Whole body images of treated animals were obtained using the IVIS Spectrum bioimaging system (PerkinElmer Life Sciences, Waltham, MA, United States) to detect the presence of formulations by dye fluorescence emission in the vaginal canal. Images were captured at 0, 1, 2, 3, 6, 7 days post-administration, and the fluorescence intensity was measured. The following instrument settings were used for comparison among different groups: exposure time 5 s, binning factor eight, excitation/emission 465/540 nm ([@B30]).

Statistical Analysis {#S2.SS8}
--------------------

Statistical analysis was performed by one-way ANOVA followed by Dunnett's test, using the Graphpad Prism 5.0 program (GraphPad, La Jolla, CA, United States), with a 95% confidence interval.

Results and Discussion {#S3}
======================

Fungal vaginitis, particularly VVC and RVVC represent important public health problems given their debilitating and long term effects on women's quality of life, including both physical and mental symptoms such as anxiety and depression, in chronic and recurrent cases ([@B39]; [@B15]). The recurrent condition also decreases women's productivity, leading to an estimated productivity loss of up to U\$\$ 14.39 billion annually ([@B15]). Current therapies are often ineffective against VVC and RVVC, with particular need for safe and effective topical treatments to improve women care.

Both AMB and MFS have broad spectrum of antifungal activity, fungicidal and post-antifungal effects ([@B16]; [@B43]). Importantly, these drugs are effective against *Candida* spp. strains resistant to azoles, and also against biofilms, which are associated with disease persistence and with increased severity of vaginal fungal infections ([@B31]; [@B47], [@B45]; [@B41]). Initially, we confirmed the antifungal activity of MFS and AMB on the *C. albicans* reference strain SC5314 using the assay described in the M27 document ([@B10]), with MIC values of 1 μg/ml and 0.12 μg/ml (for MFS and AMB, respectively), which are in agreement with values reported previously ([@B45]; [@B41]).

As AMB is an important antifungal agent since 1956, several *in vivo* studies have shown the efficacy of different formulations for AMB using animal models of invasive or cutaneous fungal infections and it is used actually to treat many candidiasis clinical forms ([@B32]). In contrast, studies *in vivo* for MFS antifungal activity is still insufficient. Previous studies reported a reduction in *Cryptococcus* dissemination in the central nervous system using murine model upon treatment with 3.6 mg/kg MFS ([@B50]); and the pre-treatment of mouse oral mucosa with an aqueous solution containing 2 mg/ml MFS decreased *Candida* infection ([@B46]). Here, we evaluated the antifungal efficacy of MFS or AMB in two nanocarriers (microemulsion and alginate nanoparticles) and compared with conventional formulation testing on vaginal candidiasis model.

In our model, we chose to treat vaginal candidiasis by the intravaginal route of administration, because local action formulations can contain high doses of active compounds without causing significant systemic side effects, by avoiding gastrointestinal contact and the "first pass" effect in the liver ([@B3]; [@B27]). The pharmaceutical forms commonly used in the topical route include creams, gels, vaginal ovules, capsules, tablets, among others; despite this variety, the major disadvantage is the fact that drug release is not prolonged and low retention to the vaginal epithelium, requiring prolonged duration of therapy and/or higher frequency of administered doses ([@B3]; [@B27]). Thus, we tested here the use of nanocarriers (microemulsions and alginate nanoparticles), in an attempt to overcome the lack of persistence in intravaginal treatment using conventional formulations.

The lipid microemulsion (ME) was developed using components generally regarded as safe and used in other vaginal/rectal formulations ([@B19]; [@B20]). Previous studies demonstrated that vaginal administration of ME composed of phosphatidylcholine and/or monoolein (as employed here) caused no local histological changes such as epithelial thickening or infiltration of inflammatory cells ([@B37]; [@B1]; [@B48]); and no decreases in cell viability was observed when the ME was used up to 10 mg/ml assessed in tumor and non-transformed epithelial cells in 2D cultures *in vitro* ([@B28]). For comparison, other ME containing larger amounts of non-ionic surfactants caused no significant reduction on the viability of fibroblasts when used at 10--50 μg/ml ([@B24]; [@B35]), indicating that the ME developed here should be safer.

ME swelling and transition to gel *in vivo* is important to prolong drug release ([@B6]; [@B35]). Thus, we verified if the ME used here would swell upon contact with an aqueous environment and undergo phase transition to gel. ME swelling was observed within the first hour of incubation with distilled water at 37°C and remained constant for 48 h ([Figure 1A](#F1){ref-type="fig"}), generating a hexagonal phase gel after 4 h of contact with water ([Figure 1E](#F1){ref-type="fig"}) unlike previous hours ([Figures 1B--D](#F1){ref-type="fig"}). This "mesophase" can be described as a two-dimensional structure containing long cylindrical arrangements as described previously by [@B29], and was maintained for 48 h in contact with water ([Figures 1E--I](#F1){ref-type="fig"}, black arrows). Moreover, the transformation of the liquid-crystalline gels *in vivo* upon uptake of vaginal fluids as well as ME non-toxic profile on mucosa and skin ([@B35]; [@B6]) are both important characteristics for topical application used here.

![Microemulsion (ME) swelling after contact with an aqueous environment. **(A)** Percentage of microemulsion swelling during 48 h of contact with water, at 37°C bath. The inset in the **(A)** is an enlarged figure in the times ranging from 1 to 4 h of incubation. Data represent mean ± SD values of three independent experiments. **(B--I)** Microemulsion morphology as seen by polarized light microscopy at the following incubation times: 1 h **(B)**, 2 h **(C)**, 3 h **(D)**, 4 h **(E)**, 6 h **(F)**, 24 h **(G)**, and 48 h **(H,I)**. The hexagonal phase, characterized by the presence of two-dimensional structure containing long cylindrical arrangements (arrows), indicates the formation of a liquid-crystalline gel capable of sustained drug delivery. The hexagonal phase is observed after 4 h of incubation with water **(E)**, and is maintained for 48 h **(H,I)**. Scale bars = 100 μm.](fmicb-10-02976-g001){#F1}

The natural polymer alginate has been explored in the last decade for development of drug delivery systems, including antifungals as azoles and polyenes, due to its non-toxicity and non-immunogenic properties when systemically or topically administered (reviewed by [@B42]). In previous studies, we demonstrated that alginate nanoparticles promoted sustained release of MFS (∼ 8% or ∼125 μg/ml) in aqueous medium for up to 24 h ([@B25]; [@B41]). Furthermore, MFS encapsulated in alginate nanoparticles showed reduced toxicity compared with free MFS, and antifungal efficacy against candidiasis and cryptococcosis, in an invertebrate model ([@B41]). Thus, we tested MFS-loaded alginate nanoparticles (MFS-AN) as an option for antifungal therapy in murine vaginitis. The MFS-AN used in this study exhibited mean size of 280 -- 350 nm, polydispersity \< 0.3 (indicating low polydispersity) and negative zeta potential of approximately -- 25 mV, in agreement with previous results from our group ([@B25]; [@B41]).

Both nanocarriers containing AMB or MFS were evaluated in murine model of vaginal candidiasis. Female BALB/c mice were infected with *C. albicans* SC 5314 (3 × 10^6^ yeasts) intravaginally due to its pathogenicity previously described in oral/vaginal mucosa ([@B49]); and this model could properly mimic complicated clinical conditions and provides a valuable means for antifungal assay *in vivo* ([@B49]). After 24 h of fungal infection, the mice were treated with AMB or MFS in microemulsions or alginate nanoparticles and compared with a conventional formulation (vaginal cream). In addition, we tested two different treatment schedules for the microemulsion treatments ("3×" and "1×," for repeated dosing every 2 days or a single dose, respectively) and only single dose for alginate nanoparticles.

Among AMB formulations, AMB-CR(6×) and AMB-ME(3×) significantly reduced the fungal burden in the vaginal tissue, but not as a single dose of AMB-ME, which did not control fungal infection ([Figure 2A](#F2){ref-type="fig"}). We observed similar results for treatment with MFS-CR(6×) and MFS-ME(3×) decreasing the fungal burden significantly compared with the untreated group, while a single dose of MFS-ME (1×) could not control the infection ([Figure 2B](#F2){ref-type="fig"}). In addition, we observed a significant reduction in fungal burden after vaginal candidiasis treatment using a single dose of MFS-AN, and the efficacy of this treatment was comparable with that of the other effective formulations ([Figure 2B](#F2){ref-type="fig"}). The semi-quantitative analysis of fungal load in vaginal tissue based on histological section examination ([Figures 2C--J](#F2){ref-type="fig"}) corroborated the fungal burden data ([Figures 2A,B](#F2){ref-type="fig"}), indicating that the treatments with AMB-ME(3×), MFS-ME(3×), and MFS-AN(1×) were more expressive, because they combined efficacy (similar or higher than that of conventional vaginal cream) with the possibility to reduce administration frequency. In addition, we also evaluated if the nanocarriers *per se* could interfere on the antifungal activity of formulations; and the CFU/g data were similar to the untreated group (data not show). Similar result was observed previously for vaginal cream using the same vaginal candidiasis model ([@B14]).

![Fungal burden of *Candida albicans* in vaginal tissue of BALB/c mice after treatment with formulations contained amphotericin B (AMB) or miltefosine (MFS) in a vaginal cream (AMB-CR and MFS-CR), in microemulsion (AMB-ME and MFS-ME) or encapsulated in alginate nanoparticles (MFS-AN). The numbers in parenthesis indicate the number of doses administered. **(A,B)** Fungal burden quantification (by colony forming units/g -- CFU/g) using a plaque assay (*n* = 5 animals/group). The amplitude of the bars is defined by the maximum and minimum values. ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01 and ^∗∗∗^*p* \< 0.001 when compared with the untreated group (one-way ANOVA, followed by Dunnett's test). **(C--J)** Hematoxylin-eosin stained histopathological sections of vaginal tissue kept untreated or treated with AMB or MFS in different formulations. Arrows indicate the fungal cells. **(C)**: untreated group; **(D)**: AMB-CR (6×); **(E)**: AMB-ME (3×); **(F)**: AMB-ME (1×); **(G)**: MFS-CR (6×); **(H)**: MFS-ME (3×); **(I)**: MFS-ME (1×); and **(J)**: MFS-AN (1×). Results of semi-quantitative fungal load analysis from vaginal tissue sections are indicated in brackets (*n* = 2 animals/group). Scale bars = 50 μm.](fmicb-10-02976-g002){#F2}

Amphotericin B and MFS incorporated into microemulsions were also effective in the control of vaginal candidiasis when used in three doses, and both antifungals presented a similar effect. The advantage of the microemulsion used here compared to the alginate-based nanoparticle is the *in situ* (i.e., in the vaginal mucosa) formation of a liquid crystalline system with a gel-like appearance upon contact with water ([@B21]; [@B29]; [@B35]). The gel formed after ME swelling is more viscous, which improves the residence time in the vaginal canal ([@B22]; [@B38]; [@B26]). Advantages resulting from this property include the lower probability of leaking after delivery and the possibility of reducing the dosing frequency compared to less viscous systems ([@B38]; [@B26]). Thus, the fluid ME can be considered a ready-to-use delivery system and does not need to be incorporated in a gel or in any other dosage form for administration since it spontaneously forms a gel *in situ*. On the contrary, alginate nanoparticles had to be incorporated in a gel for its topical application, which requires fine-tuning its viscosity for an easy administration.

To evaluate if the nanocarriers would remain longer in the vaginal canal compared to a conventional cream, we treated animals with formulations containing a fluorescent dye (Alexa Fluor 647) and assessed if the fluorescence signal persisted longer in the vaginal canal using *in vivo* imaging. Our data showed the persistence of the fluorescence signal in the vaginal canal for the duration of the treatment period using lipid- and alginate-based nanocarriers systems ([Figure 3](#F3){ref-type="fig"}). The microemulsion (ME + AF) remained in the vaginal canal for up to 7 days (Day 7), and the fluorescence intensity was significantly higher than that obtained with the vaginal cream used as conventional formulation (CR + AF) (*p* \< 0.05), which was barely detectable in the vaginal canal after 1-day post-administration (Day 1) ([Figures 3A,B](#F3){ref-type="fig"}).

![*In vivo* imaging of BALB/c female mice treated intravaginally with different drug nanocarriers labeled with Alexa Fluor 647. **(A)** Images at different time points after intravaginal administration of microemulsion with or without Alexa Fluor 647 (ME + AF and ME, respectively), vaginal cream with Alexa Fluor 647 (CR + AF) and alginate nanoparticles with or without Alexa Fluor 647 (AN + AF and AN). Colors indicate fluorescence intensity according to the scale on the right. **(B)** Fluorescence decay after administration of Alexa Fluor 647 labeled nanocarriers (*n* = 3 animals/group; values represent the fluorescence intensity median from 10 images). The fluorescence intensity in CR + AF and ME + AF was significantly above background (*p* \< 0.01 compared with ME), and the fluorescence intensity was significantly higher and more prolonged in the ME + AF group, compared with the CR + AF group (*p* \< 0.05), showing that microemulsion persists in the vaginal canal throughout the evaluation period (7 days).](fmicb-10-02976-g003){#F3}

The administration of alginate nanoparticles also resulted in fluorescence signals that persisted for up to 7 days in the vaginal canal (Day 7) ([Figure 3A](#F3){ref-type="fig"}); however, the Alexa Fluor 647 was not fully incorporated into the alginate nanoparticles, as evidenced by the lower fluorescence intensity of AN + AF right after administration (Day 0) ([Figure 3A](#F3){ref-type="fig"}). Nevertheless, we still detected considerable AN + AF fluorescence at 7 days post-administration (Day 7), suggesting that the particles provided prolonged release of the encapsulated probe ([Figure 3A](#F3){ref-type="fig"}). In addition to the fact that alginate is a polymer with strong mucoadhesive properties, we reported previously that MFS is released in a prolonged fashion when encapsulated in alginate nanoparticles ([@B25]; [@B41]); together, these two properties of alginate nanoparticles might explain the sustained antifungal effect of MFS in the MFS-AN formulation, observed here in the treatment of murine vaginal candidiasis.

MFS-AN was the best performing formulation overall, given its strong effect as a single-dose treatment. The reason for the higher antifungal efficacy of MFS-AN formulation compared to the microemulsion is unclear. One possibility is the difference in the drug release profile. However, we were not able to compare drug release from the formulations due to methodological difficulties; both drugs AMB and MFS aggregate in water-based solvents, hindering drug transport across semi-permeable membranes (employed to separate the nanocarrier from the bulk release medium), and underestimating release ([@B4]). Further studies for method adaptation are necessary to address this issue. Nevertheless, the data presented here demonstrated that MFS is active *in vivo* against vaginal infection by *Candida* in three different formulations.

In conclusion, our results demonstrated that lipid- or alginate-based nanocarrier formulations of AMB and MFS provide sustained antifungal activity after intravaginal application and may represent an important alternative for effective topical treatment of vaginal candidiasis. Compared with the standard treatment with vaginal cream, alginate nanoparticles and microemulsions reduced the number of antifungal doses required to decrease the fungal burden in infected tissues. These formulations could contribute to improve treatment and, thus, the quality of life of women diagnosed with VVC and RVVC.
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